Evidence map›Paper›PMID 40315563›Full record

ArticleThe Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases

Disseminated bartonellosis and EBV reactivation in an adolescent treated with upadacitinib.

Vincent Pargny, Emilie Delugre, Raphael Janela, Soumaya Skalli, Abdeljalil Zeggay, Hortense Petat

Abstract readCase Reports
In one paragraph

Article in The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Vincent PargnyPediatrics Department, Rouen University Hospital, France; Infectious Diseases Department, Rouen University Hospital, France. Electronic address: vincent.pargny@chu-rouen.fr.
Emilie DelugrePediatrics Department, Rouen University Hospital, France.
Raphael JanelaDermatology Department, Rouen University Hospital, France.
Soumaya SkalliDepartment of Microbiology, Rouen University Hospital, France.
Abdeljalil ZeggayInfectious Diseases Department, Rouen University Hospital, France.
Hortense PetatPediatrics Department, Rouen University Hospital, France; Univ Rouen Normandie, Université de Caen Normandie, INSERM, Normandie Univ, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBartonella henselae is responsible for disseminated infections in immunocompromised patients. Upadacitinib is a JAK inhibitor used since 2021 for the treatment of severe atopic dermatitis in adolescents over 12-years. We report here the case of disseminated Bartonellosis in a 15-year-old male treated with upadacitinib. CASE PRESENTATION: This patient presented with fever and abdominal pain. Laboratory tests showed inflammation, rhabdomyolysis and acute renal failure. Imaging studies revealed lymphadenopathies, hepatosplenic, renal and pulmonary nodules, pleural and peritoneal effusions and spleen abscesses. Bartonella henselae serology was positive for IgG and IgM. Treatment with doxycycline resolved the symptoms. We detected a concomitant EBV reactivation.

conclusionsBartonella henselae infection should be suspected in immunocompromised patients presenting with fever of unknown origin. Upadacitinib is responsible for rapid immunodepression, which can lead to viral reactivation and severe bacterial infections. Randomized controlled trials are needed to establish a consensus on treatments for the various forms of Bartonellosis.

Indexed as

Bartonella henselaeBartonella InfectionsDermatitis, AtopicEpstein-Barr Virus InfectionsHerpesvirus 4, HumanHeterocyclic Compounds, 3-RingImmunocompromised HostJanus Kinase InhibitorsLatent InfectionAcute Kidney InjuryAdolescentAnti-Bacterial AgentsDoxycyclineHumansImmunoglobulin GImmunoglobulin MAnti-Bacterial AgentsDoxycyclineHeterocyclic Compounds, 3-RingImmunoglobulin GImmunoglobulin MJanus Kinase InhibitorsupadacitinibBartonellosisImmunodepressionPediatricsUpadacitinib

Identifiers

PMID40315563
PMCPMC12084392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.